Immunodeficient Mouse Models

NCG Mice

NCG is a triple-immunodeficient mouse model. It is the first CRISPR-generated immunodeficient model developed by altering the Prkdc and Il2rg genes. It is the most immunodeficient model to date and is suitable for cells/tissues xenograft and human immune system components transplantation, enabling researchers to further study tumour biology and immuno-oncology.

The NCG model is well validated and has been available in the North American market since 2016. It is now accessible to the users in the Asia/Pacific market.

NCG (NOD/ShiLtJGPT-Prkdc^em26Cd52 Il2rg^em26Cd22)

NOD/ShiLtJGPT —–> Macrophage and DC deficient
Prkdc knockout —–> Absence of T cells and B cells
Il2rg knockout —–> Absence of NK cells

NCG Mouse Model Variants

Advantages of GemPharmatech’s Severe Immunodeficient Mouse Models

• Our comprehensive portfolio of NCG and next-generation NCG mice enables excellent engraftment of human PBMCs, HSCs, and human tumor tissues.
• Our proprietary NCG strains have an extended life span of greater than 90 weeks—approximately 15 weeks longer than for other severe immunodeficient mouse models.
• One of our next-generation NCG strains, NCG-X, enables engraftment in the absence of irradiation, promising better animal health and reduced experimental complication.
• Our large selection of PDXs provides preclinical tools for drug screening, biomarker development, and personalized medicine.
• Our collection of CDXs provide a renewable source of patient tumor materials that can be used for a variety of research applications.

Selected publications:

Zhang L, Zhu Z, Yan H, et al. Creatine promotes cancer metastasis through activation of Smad2/3. Cell Metab. 2021;33(6):1111-1123.e4. doi:10.1016/j.cmet.2021.03.009

Zhang XN, Yang KD, Chen C, et al. Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling. Cell Res. 2021;31(10):1072-1087. doi:10.1038/s41422-021-00528-3

Shao F, Liu Q, Zhu Y, et al. Targeting chondrocytes for arresting bony fusion in ankylosing spondylitis. Nat Commun. 2021;12(1):6540. Published 2021 Nov 11. doi:10.1038/s41467-021-26750-6

Documents

Immunodeficient mouse model